Skip to content
About
Company Overview
Management
Board of Directors
Scientific Advisory Board
Contact Us
Mission
Technology
Technology Overview
COVID-19
Annamycin
WP1066
WP1122
WP1732
WP1234
WP1220
Expanded Access
Pipeline
Partnerships
Science
News
Press Releases
Media Archive
Investors
Main Menu
Moleculin Biotech
A clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers and viruses.
COVID-19
Acute Myeloid Leukemia
Skin Cancer
Pancreatic Cancer
Brain Tumors
Shareholder Letter 2020
Pancreatic Cancer
Acute Myeloid Leukemia
Brain Tumors
Skin Cancer
Press Releases
Investors
Overview
Overview
Presentations
Management Team
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
FAQs
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Annual Report and Proxy
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
FAQs
All Years
2020
2019
2018
2017
2016
2015
Moleculin Biotech Inc. Announces Pricing of Initial Public Offering
May 4, 2016
Moleculin Biotech, Inc. Announces Acquisition of Annamycin Rights
Oct 28, 2015
1...
10
11
12
13
14
15
16
17
18
19
Go to Top
